Mar. 14, 2023
Ziftomenib: 2022 MOTY Nominee
Kura Oncology menin-MLL1 inhibitor
oral, QD menin-MLL1 inhibitor Ph. I/II for leukemia from HTS and SBDD ziftomenib (KO-539) Kura Oncology, San Diego, CA / UMich (Grembecka Lab)
oral, QD menin-MLL1 inhibitor Ph. I/II for leukemia from HTS and SBDD ziftomenib (KO-539) Kura Oncology, San Diego, CA / UMich (Grembecka Lab)